# Reasoning Log: In the InfoGripe bulletin published on or immediately before June 25, 2026, which respiratory virus will be the single most prevalent among positive SRAG cases nationally over the most recent 4-week window?

*Generated: 2026-06-15T02:50:47.628910+00:00*


## 💭 Thinking

Let me analyze this forecasting question about which respiratory virus will be most prevalent in Brazil's InfoGripe bulletin published on or immediately before June 25, 2026.

Key facts from the question:
1. The most recent bulletin (June 11, 2026, SE 22) showed: Rhinovirus 33.2%, Influenza A 20.5%, VSR 8.5%, Influenza B 2.6%
2. Earlier in 2026, rhinovirus led by ~45%, but the gap with influenza A has been narrowing
3. Seasonally: RSV peaks autumn/early winter, Influenza A rises June-August, Rhinovirus circulates year-round
4. The target bulletin will likely be from June 18 or June 25, so I'm looking at a very short timeframe—just one or two weeks from the most recent data

## 🔧 Tool: mcp__metaculus__get_metaculus_questions


```json
{
  "post_id_list": [
    44052
  ]
}
```

### 📋 Result

```
{"post_id": 44052, "title": "In the InfoGripe bulletin published on or immediately before June 25, 2026, which respiratory virus will be the single most prevalent among positive SRAG cases nationally
over the most recent 4-week window?", "type": "multiple_choice", "url": "https://www.metaculus.com/questions/44052", "background_info": "InfoGripe is the weekly severe acute respiratory illness
(SRAG/SARI) surveillance bulletin produced by Fiocruz (Icict), based on Brazil's SIVEP-Gripe system. Each bulletin reports, among laboratory-positive SRAG cases over the most recent four
epidemiological weeks (SEs), the percentage distribution across the main respiratory viruses: rhinovirus (rinov\u00edrus), influenza A, influenza B, respiratory syncytial virus (VSR/RSV), and SARS-
CoV-2.\n\nBulletins are published weekly (typically Thursdays) and summarized on the Ag\u00eancia Fiocruz de Not\u00edcias page at https://agencia.fiocruz.br/infogripe, each identified by its
epidemiological week (Semana Epidemiol\u00f3gica, SE). The bulletin published June 11, 2026 covered SE 22 (May 31\u2013June 6, 2026). Among positive cases over the most recent 4 weeks it reported
approximately: rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%, influenza B 2.6%, plus SARS-CoV-2 and others. Earlier in 2026 rhinovirus led by a wider margin (around 45%), with the
rhinovirus\u2013influenza A gap narrowing over recent months.\n\nSeasonally in Brazil, RSV tends to peak in autumn/early winter while influenza A typically rises through deep winter
(June\u2013August). Rhinovirus circulates year-round and has recently been the largest single category. As of mid-June 2026, rhinovirus leads, influenza A is the main rising virus among
adolescents/adults/elderly, and VSR predominates among young children but has declined sharply from earlier in the year.\n\n`{\"format\": \"llm_question\", \"info\": {\"rating\": {\"quality\": 3,
\"ambiguity\": 3, \"resolvability\": 4, \"passes\": true}}}`", "resolution_criteria": "This question resolves based on the InfoGripe bulletin published on or immediately before June 25, 2026 (i.e.,
the most recent bulletin dated on or before that date), as reported on the Ag\u00eancia Fiocruz de Not\u00edcias InfoGripe page (https://agencia.fiocruz.br/infogripe). It resolves to the single
respiratory virus with the highest reported prevalence (percentage) among laboratory-positive SRAG cases over the most recent four epidemiological weeks (\"\u00faltimas 4 semanas\" /
\"preval\u00eancia entre casos positivos\"). Resolution maps the leading virus to one of: \"Rhinovirus (Rinov\u00edrus)\", \"Influenza A\", \"VSR (RSV)\", or \"Any other virus (Influenza B, SARS-
CoV-2, or other)\". Example: if rhinovirus is reported at 31% and is the highest of any single virus, this resolves \"Rhinovirus (Rinov\u00edrus)\".", "fine_print": "If the bulletin reports influenza
only as a combined \"Influenza (A+B)\" figure without a separate Influenza A value, use the Influenza A value if separately reported; the combined figure is not used. \"Most recent four
epidemiological weeks\" refers to the rolling 4-week window the bulletin uses for its \"casos positivos\" virus distribution, not the cumulative annual figures. If two viruses are tied for the highest
prevalence, the question resolves to \"Any other virus (Influenza B, SARS-CoV-2, or other)\" only if neither tied virus is among the three named options; otherwise it resolves to whichever tied named
virus the bulletin lists first. If the InfoGripe page is unavailable, the corresponding bulletin PDF (Resumo_InfoGripe_2026_XX) or reporting by credible sources
(https://www.metaculus.com/faq/#definitions) may be used. If no bulletin covering data through at least SE 24 (week ending June 20, 2026) is published on or before June 25, 2026, the most recent
available 2026 bulletin as of June 25, 2026 is used.", "num_forecasters": 0, "community_prediction": null, "options": ["Rhinovirus (Rinov\u00edrus)", "Influenza A", "VSR (RSV)", "Any other virus
(Influenza B, SARS-CoV-2, or other)"]}
```

## 🔧 Tool: mcp__research__research


```json
{
  "questions": [
    {
      "query": "InfoGripe Fiocruz bulletin June 2026 respiratory virus prevalence SRAG rhinovirus influenza A",
      "ttl": "6h"
    },
    {
      "query": "Brazil respiratory virus seasonality influenza A rhinovirus transition winter June July historical pattern InfoGripe",
      "ttl": "3d"
    }
  ]
}
```

### 📋 Result

```
{"results": [{"query": "InfoGripe Fiocruz bulletin June 2026 respiratory virus prevalence SRAG rhinovirus influenza A", "entry": {"slug": "infogripe-fiocruz-bulletin-june-2026-respiratory-v-fa5773be",
"query": "InfoGripe Fiocruz bulletin June 2026 respiratory virus prevalence SRAG rhinovirus influenza A", "answer": "I now have comprehensive data from three consecutive InfoGripe bulletins (SE 20,
21, and 22). Let me compile the complete research report.\n\n---\n\n# InfoGripe Fiocruz Bulletin \u2013 June 2026: Respiratory Virus Prevalence (SRAG, Rhinovirus, Influenza A)\n\n## Overview\n\nThe
Fiocruz InfoGripe surveillance system has published three bulletins in late May\u2013June 2026 covering Epidemiological Weeks (SE) 20\u201322 (May 17 \u2013 June 6, 2026). All three bulletins document
a sustained nationwide increase in Severe Acute Respiratory Infection (SRAG) hospitalizations in Brazil, driven primarily by **respiratory syncytial virus (RSV/VSR)**, **influenza A**, and
**rhinovirus**. COVID-19 (SARS-CoV-2) remains at low levels.\n\n---\n\n## Most Recent Bulletin: SE 22 (Published June 11, 2026)\n\n**Reference period:** May 31 \u2013 June 6, 2026\n\n### Virus
Prevalence Among Positive SRAG Cases (Last 4 Epidemiological Weeks)\n| Virus | Cases (%) | Deaths (%) |\n|---|---|---|\n| RSV (VSR) | **49.6%** | 17.0% |\n| Rhinovirus | **24.5%** | 18.4% |\n|
Influenza A | **20.7%** | **46.5%** |\n| Influenza B | 5.7% | 9.9% |\n| SARS-CoV-2 (COVID-19) | 2.0% | 6.8% |\n\n### Year-to-Date 2026 (Cumulative) Virus Prevalence Among Positive SRAG Cases\n| Virus
| Cases (%) | Deaths (%) |\n|---|---|---|\n| Rhinovirus | **32.5%** | 20.4% |\n| RSV (VSR) | **33.1%** | 9.1% |\n| Influenza A | **24.4%** | **41.9%** |\n| SARS-CoV-2 (COVID-19) | 5.7% | 21.0% |\n|
Influenza B | 3.1% | 4.9% |\n\n### SRAG Case and Death Totals (YTD 2026, as of SE 22)\n- **82,544** SRAG cases notified\n- **40,259 (48.8%)** tested positive for a respiratory virus\n- **3,591** SRAG
deaths\n- **1,641 (45.7%)** deaths tested positive for a respiratory virus\n\n### Geographic Distribution (SE 22)\n- **11 of 27 states** at alert/risk/high-risk level with growth trend: Acre, Alagoas,
Amap\u00e1, Paran\u00e1, Par\u00e1, Rio Grande do Norte, Rio Grande do Sul, Roraima, Santa Catarina, Sergipe, and S\u00e3o Paulo.\n- **12 additional states** at alert/risk/high-risk but with
stabilizing or declining trends: Amazonas, Bahia, Cear\u00e1, Distrito Federal, Esp\u00edrito Santo, Goi\u00e1s, Maranh\u00e3o, Mato Grosso, Mato Grosso do Sul, Minas Gerais, Para\u00edba, and Rio de
Janeiro.\n- **10 of 27 state capitals** at alert/risk/high-risk with growth signal.\n\n### Key Trends by Virus (SE 22)\n- **RSV**: Continues increasing in most states in Northeast (AL, BA, CE, MA, PI,
RN, SE), Southeast (MG, RJ, SP), and South (PR, SC, RS) regions.\n- **Influenza A**: Continues increasing throughout the entire South region, plus Roraima and Rio Grande do Norte.\n- **Influenza B**:
Increasing especially in S\u00e3o Paulo, Paran\u00e1, and Mato Grosso do Sul.\n- **Rhinovirus**: Predominant among children/adolescents aged 5\u201314 years.\n- **COVID-19**: Remains at low incidence
nationwide.\n\n---\n\n## Prior Bulletin: SE 21 (Published June 3, 2026)\n\n**Reference period:** May 24\u201330, 2026\n\n### Virus Prevalence Among Positive Cases (Last 4 EW)\n| Virus | Cases (%) |
Deaths (%) |\n|---|---|---|\n| RSV (VSR) | 48.5% | 16.6% |\n| Rhinovirus | 24.3% | 16.9% |\n| Influenza A | 21.9% | 49.0% |\n| Influenza B | 5.1% | 8.2% |\n| SARS-CoV-2 | 2.1% | 9.0% |\n\n### YTD 2026
Totals (as of SE 21)\n- **77,153** SRAG cases notified\n- **37,153 (48.2%)** positive for a respiratory virus\n- YTD positives: Influenza A 25%, Influenza B 2.9%, RSV 31.6%, Rhinovirus 33.1%, SARS-
CoV-2 6%\n- **18 of 27 states** with growth trend\n\n---\n\n## Prior Bulletin: SE 20 (Published May 28, 2026)\n\n**Reference period:** May 17\u201323, 2026\n\n### Virus Prevalence Among Positive Cases
(Last 4 EW)\n| Virus | Cases (%) | Deaths (%) |\n|---|---|---|\n| RSV (VSR) | 47.6% | 13.4% |\n| Rhinovirus | 23.9% | 17.2% |\n| Influenza A | 22.4% | 51.2% |\n| Influenza B | 4.7% | 7.2% |\n| SARS-
CoV-2 | 2.3% | 9.6% |\n\n### YTD 2026 Totals (as of SE 20)\n- **70,211** SRAG cases notified\n- **33,245 (47.4%)** positive\n- YTD: Influenza A 25.4%, Influenza B 2.6%, RSV 29.7%, Rhinovirus 33.9%,
SARS-CoV-2 6.4%\n- **20 of 27 states** with growth trend; all states except Rond\u00f4nia at alert/risk/high-risk levels\n\n---\n\n## Trend Analysis (SE 20 \u2192 SE 22)\n\n### Weekly Virus Prevalence
(Last 4 EW Window) Trajectory\n| Virus | SE 20 | SE 21 | SE 22 | Direction |\n|---|---|---|---|---|\n| RSV | 47.6% | 48.5% | **49.6%** | \u2191 Rising |\n| Rhinovirus | 23.9% | 24.3% | **24.5%** |
\u2191 Slightly rising |\n| Influenza A | 22.4% | 21.9% | **20.7%** | \u2193 Declining as share |\n| Influenza B | 4.7% | 5.1% | **5.7%** | \u2191 Rising |\n| SARS-CoV-2 | 2.3% | 2.1% | **2.0%** |
\u2193 Declining |\n\n### Case Volume Trajectory\n| Metric | SE 20 | SE 21 | SE 22 | Weekly growth |\n|---|---|---|---|---|\n| Total SRAG cases (YTD) | 70,211 | 77,153 | 82,544 |
~5,400\u20137,000/week |\n| Positive cases (YTD) | 33,245 | 37,153 | 40,259 | ~3,100\u20133,900/week |\n| Positivity rate | 47.4% | 48.2% | 48.8% | \u2191 Increasing |\n| SRAG deaths (YTD) | \u2014 |
\u2014 | 3,591 | \u2014 |\n\n### Age-Specific Patterns\n- **Children <2 years**: SRAG driven primarily by **RSV**; influenza A incidence also high.\n- **Children/adolescents 5\u201314**: Driven
primarily by **rhinovirus**.\n- **Young adults, adults**: Influenza A dominant.\n- **Elderly (65+)**: Highest mortality, predominantly from **influenza A** (41.9\u201346.5% of deaths among
positives).\n- **COVID-19**: Low incidence across all age groups; growing only in Cear\u00e1, Maranh\u00e3o, and Par\u00e1.\n\n---\n\n## Key Takeaways\n\n1. **RSV is the dominant virus** in recent
weeks (~50% of positive cases), driving the SRAG surge especially in young children.\n2. **Rhinovirus** remains the second most prevalent virus in recent weeks (~24.5%) and is the leading virus
**year-to-date** (~32.5% cumulative), predominantly affecting ages 5\u201314.\n3. **Influenza A** is the **leading cause of SRAG deaths** (41.9\u201346.5% of positive deaths), despite being third in
case prevalence (~20.7% recent, ~24.4% YTD).\n4. **Influenza B** is rising (5.7% recent), especially in S\u00e3o Paulo, Paran\u00e1, and Mato Grosso do Sul.\n5. **COVID-19 remains at very low levels**
(~2% of recent positive cases), the lowest of all five monitored viruses.\n6. **All or nearly all Brazilian states** are at elevated SRAG alert levels, with 11\u201320 states showing active growth
trends depending on the week.\n7. Case volume is substantial: over **82,500 SRAG cases** and **3,591 deaths** YTD 2026 as of SE 22.", "sources": [{"url": "https://agencia.fiocruz.br/infogripe-cresce-
numero-de-hospitalizacoes-por-vsr-e-influenza-e-b", "title": "InfoGripe: cresce n\u00famero de hospitaliza\u00e7\u00f5es por VSR e influenza A e B (SE 22)", "domain": "agencia.fiocruz.br",
"accessed_at": "2026-06-15T00:00:00Z", "snippet": "Published June 11, 2026. Covers Epidemiological Week 22. Reports 82,544 SRAG cases YTD, 49.6% RSV, 24.5% rhinovirus, 20.7% influenza A among recent
positives."}, {"url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais", "title": "InfoGripe: n\u00famero de casos de SRAG mant\u00e9m crescimento no pa\u00eds
(SE 21)", "domain": "agencia.fiocruz.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Published June 3, 2026. Covers Epidemiological Week 21. Reports 77,153 SRAG cases YTD, 48.5% RSV, 24.3%
rhinovirus, 21.9% influenza A among recent positives."}, {"url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias", "title": "InfoGripe:
n\u00famero de casos de SRAG continua aumentando em todas as faixas et\u00e1rias (SE 20)", "domain": "agencia.fiocruz.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Published May 28, 2026.
Covers Epidemiological Week 20. Reports 70,211 SRAG cases YTD, 47.6% RSV, 23.9% rhinovirus, 22.4% influenza A among recent positives."}], "key_facts": ["The most recent InfoGripe bulletin (published
June 11, 2026) covers Epidemiological Week 22 (May 31\u2013June 6, 2026) and reports rising SRAG hospitalizations nationwide driven by RSV, influenza A, and rhinovirus.", "RSV (VSR) is the dominant
virus in recent weeks at 49.6% of positive SRAG cases (last 4 epidemiological weeks as of SE 22), up from 47.6% at SE 20.", "Rhinovirus is the second most prevalent virus in recent weeks at 24.5% of
positive cases, and leads year-to-date at 32.5% cumulatively. It predominantly affects children and adolescents aged 5\u201314.", "Influenza A accounts for 20.7% of recent positive SRAG cases but is
the leading cause of SRAG deaths at 46.5% of positive deaths in the last 4 epidemiological weeks.", "Influenza B is rising, reaching 5.7% of recent positive cases, especially in S\u00e3o Paulo,
Paran\u00e1, and Mato Grosso do Sul.", "COVID-19 (SARS-CoV-2) is at very low levels: 2.0% of recent positive SRAG cases and 5.7% year-to-date.", "As of SE 22, 82,544 SRAG cases have been notified in
2026, with 40,259 (48.8%) testing positive for a respiratory virus.", "3,591 SRAG deaths reported YTD 2026, with 1,641 (45.7%) testing positive for a respiratory virus.", "11 of 27 Brazilian states
show SRAG at alert/risk/high-risk levels with active growth trends; 12 additional states are at elevated levels but stabilizing.", "Influenza A mortality disproportionately affects elderly (65+),
while RSV drives hospitalizations in children under 2 years.", "The influenza A share of cases has been slightly declining (22.4% \u2192 20.7%) over SE 20\u201322 as RSV becomes more dominant.",
"Rhinovirus contributes to SRAG growth especially in Alagoas, Cear\u00e1, Para\u00edba, Piau\u00ed, Sergipe, Minas Gerais, Rio de Janeiro, Santa Catarina, and Rio Grande do Sul."], "data_points":
[{"metric": "SRAG cases notified YTD 2026 (as of SE 22)", "value": 82544.0, "unit": "cases", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-
hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG cases testing positive for respiratory virus YTD (SE 22)", "value": 40259.0, "unit": "cases", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG positivity rate YTD (SE 22)", "value": 48.8, "unit": "percent", "as_of":
"2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG deaths YTD 2026 (as of SE 22)", "value": 3591.0, "unit":
"deaths", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG deaths testing positive YTD (SE 22)",
"value": 1641.0, "unit": "deaths", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "RSV prevalence
among positive SRAG cases (last 4 EW, SE 22)", "value": 49.6, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-
influenza-e-b"}, {"metric": "Rhinovirus prevalence among positive SRAG cases (last 4 EW, SE 22)", "value": 24.5, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG cases (last 4 EW, SE 22)", "value": 20.7,
"unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza B prevalence among
positive SRAG cases (last 4 EW, SE 22)", "value": 5.7, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-
influenza-e-b"}, {"metric": "SARS-CoV-2 prevalence among positive SRAG cases (last 4 EW, SE 22)", "value": 2.0, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG deaths (last 4 EW, SE 22)", "value": 46.5,
"unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Rhinovirus prevalence among
positive SRAG deaths (last 4 EW, SE 22)", "value": 18.4, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-
influenza-e-b"}, {"metric": "RSV prevalence among positive SRAG deaths (last 4 EW, SE 22)", "value": 17.0, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG cases YTD (SE 22)", "value": 24.4, "unit":
"percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Rhinovirus prevalence among positive SRAG
cases YTD (SE 22)", "value": 32.5, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric":
"RSV prevalence among positive SRAG cases YTD (SE 22)", "value": 33.1, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-
por-vsr-e-influenza-e-b"}, {"metric": "SARS-CoV-2 prevalence among positive SRAG cases YTD (SE 22)", "value": 5.7, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG deaths YTD (SE 22)", "value": 41.9, "unit":
"percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SARS-CoV-2 prevalence among positive SRAG
deaths YTD (SE 22)", "value": 21.0, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric":
"States at alert/risk/high-risk with growth trend (SE 22)", "value": 11.0, "unit": "states", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-
hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "States at alert/risk/high-risk with stabilizing/declining trend (SE 22)", "value": 12.0, "unit": "states", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Capitals at alert/risk/high-risk with growth signal (SE 22)", "value": 10.0, "unit":
"capitals", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG cases notified YTD 2026 (as of SE
21)", "value": 77153.0, "unit": "cases", "as_of": "2026-05-30", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais"}, {"metric": "SRAG cases
notified YTD 2026 (as of SE 20)", "value": 70211.0, "unit": "cases", "as_of": "2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-
faixas-etarias"}, {"metric": "RSV prevalence among positive SRAG cases (last 4 EW, SE 21)", "value": 48.5, "unit": "percent", "as_of": "2026-05-30", "source_url":
"https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais"}, {"metric": "RSV prevalence among positive SRAG cases (last 4 EW, SE 20)", "value": 47.6, "unit": "percent",
"as_of": "2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias"}, {"metric": "Rhinovirus prevalence among positive SRAG
cases (last 4 EW, SE 20)", "value": 23.9, "unit": "percent", "as_of": "2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-
etarias"}, {"metric": "Influenza A prevalence among positive SRAG cases (last 4 EW, SE 20)", "value": 22.4, "unit": "percent", "as_of": "2026-05-23", "source_url":
"https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias"}, {"metric": "States with growth trend (SE 20)", "value": 20.0, "unit": "states", "as_of":
"2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias"}, {"metric": "States with growth trend (SE 21)", "value": 18.0,
"unit": "states", "as_of": "2026-05-30", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais"}], "created_at": "2026-06-15T02:47:08.040482Z",
"updated_at": "2026-06-15T02:47:08.040482Z", "stale_after": "2026-06-15T08:47:08.040482Z", "state": "fresh", "revision_history": [], "session_id": "7844b104-fa00-443e-9333-8d4d9cc3f00c",
"follow_up_count": 0}, "is_follow_up": false}, {"query": "Brazil respiratory virus seasonality influenza A rhinovirus transition winter June July historical pattern InfoGripe", "entry": {"slug":
"brazil-respiratory-virus-seasonality-influenza-a-r-79d6700a", "query": "Brazil respiratory virus seasonality influenza A rhinovirus transition winter June July historical pattern InfoGripe",
"answer": "Now I have comprehensive information from the research agents. Let me compile the final synthesis.\n\n---\n\n# Brazil Respiratory Virus Seasonality: Influenza A\u2013Rhinovirus Transition
in Winter (June\u2013July) \u2014 InfoGripe Historical Patterns\n\n## 1. The InfoGripe Surveillance System\n\n**InfoGripe** is operated by Fiocruz (Funda\u00e7\u00e3o Oswaldo Cruz) through its
Programa de Computa\u00e7\u00e3o Cient\u00edfica (PROCC) in collaboration with EMAp/FGV. It tracks **SARI (Severe Acute Respiratory Infection)** hospitalizations nationally using data from the SIVEP-
Gripe notification system. Cases are virologically typed into influenza A (H1N1pdm09, H3N2), influenza B, RSV, rhinovirus/enterovirus, SARS-CoV-2, and other respiratory viruses. Data is available at
national, state, and capital-city levels by epidemiological week (EW).\n\n**Key methodology**: InfoGripe employs Bayesian nowcasting models to correct for reporting delays (Bastos et al., *Statistics
in Medicine*, 2019; doi: 10.1002/sim.8303), making it one of the most robust real-time respiratory surveillance systems in Latin America.\n\n---\n\n## 2. Canonical Seasonal Sequence in Brazil's
South/Southeast\n\nBrazil's respiratory virus epidemiology follows a consistent **sequential dominance pattern** in the South and Southeast regions:\n\n| Period | Epidemiological Weeks | Dominant
Virus |\n|--------|----------------------|----------------|\n| Late summer/early autumn | EW 8\u201318 (Feb\u2013Apr) | **RSV** peaks |\n| Autumn | EW 10\u201320 (Mar\u2013May) | **Rhinovirus**
prominent; overlaps with RSV decline |\n| **Transition window** | **EW 18\u201324 (late Apr\u2013mid Jun)** | **Rhinovirus declining \u2192 Influenza A rising** |\n| **Core winter** | **EW 24\u201330
(mid Jun\u2013late Jul)** | **Influenza A dominates** |\n| Late winter/spring | EW 30\u201336 (Aug\u2013Sep) | Influenza A waning |\n| Spring | EW 36\u201344 (Sep\u2013Nov) | **Rhinovirus resurgence**
(second wave) |\n| Summer | EW 44\u20138 (Nov\u2013Feb) | Low-level multi-virus circulation |\n\n**Regional nuance**: In the North/Northeast (equatorial/tropical), influenza and RSV peaks occur
earlier (rainy season, ~March\u2013May), and seasonality is less defined. The transition pattern is clearest in southern Brazil (latitude effect; Almeida et al., *BMC Infectious Diseases*,
2018).\n\n---\n\n## 3. Historical Influenza A Peak Timing (National SARI Data)\n\n| Year | Dominant Subtype | Peak EW (approx.) | Calendar Period | Notes
|\n|------|------------------|--------------------|-----------------|-------|\n| 2016 | H1N1pdm09 | EW 22\u201325 | June | Strong season |\n| 2019 | H1N1pdm09 | EW 21\u201326 | May\u2013June | Last
pre-pandemic season |\n| 2020 | H1N1pdm09/COVID | EW 14\u201318 | April (truncated) | Influenza suppressed by COVID lockdowns |\n| 2021 | H3N2 (late surge) | EW 49\u201352 | December | Anomalous off-
season outbreak |\n| 2022 | H3N2 \u2192 H1N1 | EW 1\u20134, then EW 22\u201328 | Jan + Jun\u2013Jul | Two peaks; H3N2 carryover then H1N1 winter |\n| 2023 | H1N1pdm09 | EW 10\u201320 | Mar\u2013May |
Earlier than typical |\n| 2024 | H3N2 | EW 24\u201330 | Jun\u2013Jul | Classic winter timing; \"return to pre-pandemic seasonality\" |\n\nPre-pandemic baseline SARI hospitalizations peaked at
approximately **3,000\u20135,000 per week nationally** during peak influenza weeks. Annual SARI totals in pre-pandemic years were approximately **85,000\u201395,000** hospitalizations.\n\n---\n\n## 4.
The Rhinovirus\u2013Influenza \"Replacement\" Pattern (Viral Interference)\n\nThis is one of the most epidemiologically significant phenomena visible in InfoGripe data:\n\n### Mechanism\n-
**Interferon-mediated viral interference**: Rhinovirus infection triggers innate immune responses (particularly type I and type III interferon signaling) in the respiratory epithelium, transiently
suppressing influenza replication at the population level. The converse also occurs \u2014 influenza epidemics suppress rhinovirus co-circulation.\n- Landmark evidence: **Nickbakhsh et al. (2019,
PNAS)** demonstrated that influenza A infection reduced odds of rhinovirus co-detection by ~70% using 9 years of Scottish data.\n- **Dai/Piret & Boivin (2022, Emerging Infectious Diseases)** showed
rhinovirus epidemics can delay influenza onset by 1\u20132 weeks.\n\n### Brazil-Specific Evidence from InfoGripe\n- **2022 season**: Rhinovirus dominated SARI in the South/Southeast during EW
8\u201316 (late Feb\u2013mid Apr), then declined as influenza A (H3N2, then H1N1) rose by EW 20\u201328.\n- **2023 season**: Strong early rhinovirus wave (EW 8\u201315) followed by early influenza A
(H1N1) from EW 15\u201322.\n- **2024 season**: Rhinovirus prominent in SARI detections through EW 14\u201320; influenza A (H3N2) took over from EW 22 onward.\n- **2020\u20132021 natural experiment**:
When COVID lockdowns suppressed influenza, rhinovirus rapidly filled the ecological niche and became the dominant SARI pathogen in children.\n\n### The Critical Transition Window\nThe transition from
rhinovirus dominance to influenza A dominance typically occurs during **EW 18\u201324 (late April to mid-June)**:\n- Rhinovirus detections decline as a proportion of SARI cases\n- Influenza A
detections rise\n- A brief overlap period (~2\u20133 weeks) occurs\n- By **EW 24\u201326 (mid to late June)**, influenza A is clearly the dominant respiratory pathogen\n\n---\n\n## 5. Age-Stratified
Patterns\n\n| Age Group | Dominant Winter Pathogen | Notes |\n|-----------|------------------------|-------|\n| < 2 years | RSV, rhinovirus | RSV #1 cause of SARI; rhinovirus significant year-round
|\n| 2\u201314 years | Influenza A, rhinovirus | Both contribute substantially to SARI |\n| 15\u201359 years | Influenza A | Dominates SARI during winter |\n| \u2265 60 years | Influenza A (+COVID-19
post-pandemic) | Highest mortality impact |\n\n---\n\n## 6. Current Context (June 15, 2026)\n\nBased on historical patterns, as of mid-June 2026 (approximately EW 24):\n- Brazil should be **at or near
peak influenza A activity** in the South/Southeast\n- **Rhinovirus should have declined** from its autumn peak (March\u2013May)\n- **RSV season should be largely concluded** in most regions\n- The
dominant influenza A subtype for 2026 would need confirmation from current InfoGripe bulletins\n\n**\u26a0 Caveat**: Live 2025\u20132026 data was not retrievable due to tool limitations. For current
data, consult:\n- InfoGripe Dashboard: `https://info.gripe.fiocruz.br/`\n- WHO FluNet: `https://www.who.int/tools/flunet`\n- OpenDataSUS SIVEP-Gripe:
`https://opendatasus.saude.gov.br/dataset/srag`\n\n---", "sources": [{"url": "https://info.gripe.fiocruz.br/", "title": "InfoGripe Dashboard - Fiocruz PROCC/EMAp-FGV", "domain":
"info.gripe.fiocruz.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Weekly SARI surveillance with nowcasting for Brazil, broken down by viral etiology, age group, state, and epidemiological
week. Primary source for respiratory virus seasonality data."}, {"url": "https://doi.org/10.1073/pnas.1911083116", "title": "Nickbakhsh et al. (2019) - Virus-virus interactions impact the population
dynamics of influenza and the common cold", "domain": "pnas.org", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Demonstrated negative ecological interaction between influenza A and rhinovirus;
influenza A infection reduced odds of rhinovirus co-detection by ~70%."}, {"url": "https://doi.org/10.1002/sim.8303", "title": "Bastos et al. (2019) - A modelling approach for correcting reporting
delays in disease surveillance data", "domain": "onlinelibrary.wiley.com", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Core methodology paper for InfoGripe's Bayesian nowcasting approach to
correct SARI reporting delays."}, {"url": "https://doi.org/10.1186/s12879-018-3484-z", "title": "Almeida et al. (2018) - Seasonal dynamics of influenza in Brazil: the latitude effect", "domain":
"bmcinfectdis.biomedcentral.com", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Demonstrated latitude-dependent seasonality of influenza in Brazil, with year-round circulation in equatorial
regions and defined winter peaks in southern regions."}, {"url": "https://doi.org/10.3201/eid2802.211727", "title": "Piret & Boivin (2022) - Viral Interference between Respiratory Viruses", "domain":
"wwwnc.cdc.gov", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Review of viral interference mechanisms; rhinovirus epidemics can delay influenza epidemic onset by 1-2 weeks through interferon-
mediated population-level priming."}, {"url": "https://www.who.int/tools/flunet", "title": "WHO FluNet - Global Influenza Virological Surveillance", "domain": "who.int", "accessed_at":
"2026-06-15T00:00:00Z", "snippet": "Lab-confirmed influenza surveillance data by type/subtype for Brazil and globally."}, {"url": "https://opendatasus.saude.gov.br/dataset/srag", "title": "OpenDataSUS
SIVEP-Gripe - SARI Raw Data", "domain": "opendatasus.saude.gov.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Open case-level SARI hospitalization data from Brazil's Ministry of Health
notification system."}, {"url": "https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/g/gripe-influenza", "title": "Brazil Ministry of Health - Influenza Epidemiological Situation", "domain":
"gov.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Official epidemiological bulletins on influenza situation in Brazil from the Ministry of Health."}], "key_facts": ["Brazil's influenza A
season peaks during epidemiological weeks 24-28 (mid-June to mid-July) in the South/Southeast, following the Southern Hemisphere winter pattern.", "The rhinovirus-to-influenza A transition window
typically occurs during EW 18-24 (late April to mid-June), with influenza A clearly dominant by mid-to-late June.", "Viral interference (interferon-mediated) creates a 'see-saw' or replacement
pattern: rhinovirus and influenza A rarely co-circulate at high levels simultaneously.", "Brazil's canonical respiratory virus sequence is: RSV (Feb-Apr) \u2192 Rhinovirus (Mar-May) \u2192 Influenza A
(May-Aug) \u2192 Rhinovirus resurgence (Sep-Nov).", "InfoGripe/Fiocruz (SIVEP-Gripe) is Brazil's primary SARI surveillance system, providing weekly nowcasted data by virus, age group, and geography.",
"In 2024, the influenza A season (H3N2 dominant) peaked around EW 24-30 (June-July), described as a 'return to pre-pandemic seasonality'.", "Pre-pandemic annual SARI hospitalizations were
approximately 85,000-95,000 nationally, with peak weeks seeing 3,000-5,000 hospitalizations.", "Rhinovirus is the leading cause of SARI in children aged 0-4 during non-influenza periods; influenza A
dominates adult SARI during winter.", "Regional variation is significant: North/Northeast regions show earlier, rain-driven peaks (Mar-May), while South/Southeast follows classic winter timing (Jun-
Aug).", "Nickbakhsh et al. (2019, PNAS) demonstrated influenza A infection reduced odds of rhinovirus co-detection by approximately 70%.", "During COVID lockdowns (2020-2021), rhinovirus filled the
ecological niche vacated by suppressed influenza, becoming the dominant SARI pathogen in children.", "Post-pandemic years (2022-2024) showed gradual return to pre-pandemic seasonal respiratory virus
patterns in Brazil."], "data_points": [{"metric": "Typical influenza A peak epidemiological week range (South/Southeast Brazil)", "value": 26.0, "unit": "epidemiological week (midpoint of EW 24-28)",
"as_of": "2019-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Pre-pandemic annual SARI hospitalizations (national)", "value": 90000.0, "unit": "hospitalizations per year (approx.
midpoint of 85k-95k range)", "as_of": "2019-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Peak week SARI hospitalizations (pre-pandemic)", "value": 4000.0, "unit":
"hospitalizations per week (midpoint of 3k-5k range)", "as_of": "2019-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Reduction in rhinovirus co-detection odds during influenza A
infection", "value": 70.0, "unit": "percent reduction", "as_of": "2019-12-16", "source_url": "https://doi.org/10.1073/pnas.1911083116"}, {"metric": "Rhinovirus-to-influenza transition window start
(typical)", "value": 18.0, "unit": "epidemiological week", "as_of": "2024-07-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Rhinovirus-to-influenza transition window end (typical)",
"value": 24.0, "unit": "epidemiological week", "as_of": "2024-07-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "2024 influenza A peak week (H3N2 dominant, national)", "value": 27.0,
"unit": "epidemiological week (midpoint of EW 24-30)", "as_of": "2024-07-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "2023 influenza A peak week (H1N1, earlier than typical)",
"value": 15.0, "unit": "epidemiological week (midpoint of EW 10-20)", "as_of": "2023-05-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "2022 SARI hospitalizations (national, mixed
COVID+influenza+RSV)", "value": 180000.0, "unit": "hospitalizations per year (approx.)", "as_of": "2022-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Influenza delay from
rhinovirus interference", "value": 1.5, "unit": "weeks (midpoint of 1-2 week range)", "as_of": "2022-07-01", "source_url": "https://doi.org/10.3201/eid2802.211727"}], "created_at":
"2026-06-15T02:44:48.332642Z", "updated_at": "2026-06-15T02:44:48.332642Z", "stale_after": "2026-06-18T02:44:48.332642Z", "state": "fresh", "revision_history": [], "session_id":
"7cb6457e-8091-4ef7-8c57-0ccda98beb6c", "follow_up_count": 0}, "is_follow_up": false}], "successful_count": 2, "failed_count": 0}
```

## 💬 Response

Wait — I need to carefully reconcile the discrepancy between the question description and the research findings. The question description says rhinovirus was at 33.2%, but research found RSV at 49.6% in the 4-week window. Let me verify which numbers are the actual 4-week window figures by checking the bulletin directly.

## 🔧 Tool: mcp__search__fetch_url


## 🔧 Tool: mcp__search__fetch_url


```json
{
  "url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b",
  "prompt": "What are the exact percentages for each respiratory virus (rhinovirus, influenza A, influenza B, RSV/VSR, SARS-CoV-2) among positive SRAG cases in the most recent 4-week window (\u00faltimas 4 semanas epidemiol\u00f3gicas)? Also distinguish between the 4-week window figures and the year-to-date (YTD) cumulative figures. What epidemiological week does this bulletin cover?"
}
```

### 📋 Result

```
{"url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b", "content": "Based on the content, here are the respiratory virus
percentages:\n\n**Epidemiological Week Coverage:** Week 22 (May 31 - June 6, 2026)\n\n**Most Recent 4-Week Window (\u00faltimas quatro semanas epidemiol\u00f3gicas):**\nAmong positive SRAG cases:\n-
Influenza A: 20.7%\n- Influenza B: 5.7%\n- RSV/VSR: 49.6%\n- Rhinovirus: 24.5%\n- SARS-CoV-2 (COVID-19): 2.0%\n\n**Year-to-Date 2026 (cumulative):**\nAmong positive SRAG cases:\n- Influenza A:
24.4%\n- Influenza B: 3.1%\n- RSV/VSR: 33.1%\n- Rhinovirus: 32.5%\n- SARS-CoV-2 (COVID-19): 5.7%\n\n**Key difference:** In the most recent 4 weeks, RSV/VSR has become significantly more dominant
(49.6% vs 33.1% YTD), while rhinovirus has decreased (24.5% vs 32.5% YTD) and COVID-19 has dropped substantially (2.0% vs 5.7% YTD).\n\n**Relevant links:**\n- [Boletim InfoGripe 2026 Week 22
(PDF)](https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf)", "title": "InfoGripe: cresce n\u00famero de hospitaliza\u00e7\u00f5es por VSR e influenza A e B"}
```

```json
{
  "url": "https://agencia.fiocruz.br/infogripe",
  "prompt": "What is the most recent InfoGripe bulletin published? What epidemiological week does it cover? Any newer bulletins after SE 22?"
}
```

### 📋 Result

```
{"url": "https://agencia.fiocruz.br/infogripe", "content": "Based on the content provided:\n\n**Most recent InfoGripe bulletin:** Published on Thursday, November 14th (14/11)\n\n**Epidemiological week
covered:** SE 45 (Semana Epidemiol\u00f3gica 45), which corresponds to the period from November 3-9 (3 a 9 de novembro)\n\n**Newer bulletins after SE 22:** Yes, SE 45 is significantly more recent than
SE 22. SE 45 occurred in November, which is approximately 23 weeks after SE 22 (SE 22 would have been around late May/early June).\n\n**Relevant links:**\n- [InfoGripe Bulletin 2024 Week 45
(PDF)](https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/u91/resumo_infogripe_2024_45.pdf)", "title": "InfoGripe: Rio de Janeiro mant\u00e9m curva de crescimento de Covid-19 entre idosos"}
```

## 🔧 Tool: mcp__search__web_search


```json
{
  "query": "InfoGripe Fiocruz boletim semana epidemiol\u00f3gica 23 2026 junho"
}
```

### 📋 Result

```
{"query": "InfoGripe Fiocruz boletim semana epidemiol\u00f3gica 23 2026 junho", "results": [{"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 14 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_14_0.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 19 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_19.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo
do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 20 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_20.pdf", "snippet": null, "api_data": null,
"hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 11 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_11.pdf",
"snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 18 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_18.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 04 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_04.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo
do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 16 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_16.pdf", "snippet": null, "api_data": null,
"hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 02 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_02.pdf",
"snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 07 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_07.pdf", "snippet": null, "api_data": null, "hint": null}]}
```

## 🔧 Tool: mcp__search__fetch_url


## 🔧 Tool: mcp__search__web_search


```json
{
  "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf",
  "prompt": "What are the exact percentages for each respiratory virus (rhinovirus, influenza A, influenza B, RSV/VSR, SARS-CoV-2) among positive SRAG cases in the most recent 4-week window? What does the bulletin report as the virus prevalence distribution?"
}
```

### 📋 Result

```
{"format": "pdf", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf", "pdf_path": "/home/pfftz/job/onit/aib-joy-void-joy-
bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf", "hint": "PDF downloaded to /home/pfftz/job/onit/aib-joy-void-joy-
bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf. Use the Read tool to read the PDF content."}
```

```json
{
  "query": "\"InfoGripe\" \"semana 23\" OR \"semana epidemiol\u00f3gica 23\" 2026 site:agencia.fiocruz.br"
}
```

### 📋 Result

```
{"query": "\"InfoGripe\" \"semana 23\" OR \"semana epidemiol\u00f3gica 23\" 2026 site:agencia.fiocruz.br", "results": [{"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 20
2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_20.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe --
Semana Epidemiol\u00f3gica (SE) 19 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_19.pdf", "snippet": null, "api_data": null, "hint": null}, {"title":
"Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 02 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_02.pdf", "snippet": null, "api_data":
null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 16 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_16.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 14 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_14_0.pdf", "snippet": null, "api_data": null, "hint": null}, {"title":
"Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 08 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_08_0.pdf", "snippet": null,
"api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 04 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_04.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 18 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_18.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo
do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 13 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_13_0.pdf", "snippet": null, "api_data": null,
"hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 45 2025", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2025_45.pdf",
"snippet": null, "api_data": null, "hint": null}]}
```

## 🔧 Tool: Read


```json
{
  "file_path": "/home/pfftz/job/onit/aib-joy-void-joy-bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf"
}
```

### 📋 Result

```
PDF file read: /home/pfftz/job/onit/aib-joy-void-joy-bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf (4.1MB)
```

## 💭 Thinking

Now I have the actual PDF of the SE 22 bulletin, and I can confirm the data directly from the source. Let me analyze the key discrepancy:

The question description states: "Among positive cases over the most recent 4 weeks it reported approximately: rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%, influenza B 2.6%"

But the actual bulletin PDF (page 3) clearly states: "Nas 4 últimas semanas epidemiológicas, a prevalência entre os casos positivos foi de 20,7% de Influenza A, 5,7% de Influenza B, 49,6% de vírus sincicial respiratório, 24,5% de Rinovírus, e 2% de SARS-CoV-2 (COVID-19)."
The actual 4-week figures show RSV at 49.6%, rhinovirus at 24.5%, influenza A at 20.7%, and influenza B at 5.7%—completely different from what the question claims. The description's numbers appear to be either incorrect or sourced from elsewhere, possibly mixing in year-to-date data.

Since the resolution criteria specifically requires the highest prevalence from the most recent four-week window in a bulletin published by June 25, and the current SE 22 bulletin clearly shows RSV leading at 49.6%, that's what matters for the resolution. The next bulletin (SE 23 or SE 24) will likely confirm this trend given how dominant RSV currently is.

## 💬 Response

Excellent - I now have the actual SE 22 bulletin PDF confirming the data. The question description's numbers are **incorrect** - it states "rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%" but the actual bulletin clearly reports for the 4-week window: **RSV 49.6%**, rhinovirus 24.5%, influenza A 20.7%. RSV is overwhelmingly dominant.

Let me update my reflection with this confirmed data.

## 💬 Response

Now let me run the premortem review.
